MilliporeSigma Webinars

31. Advancements In Process And Payload Development 2/29/2024

    Continuous advancements in the process and payload development of ADCs and next-generation bioconjugates have the potential to progress targeted therapeutics and improve patient treatment options.

32. Enable Upstream Intensified Bioprocessing Using Modular Bioreactors 1/19/2024

    Discover a new technology that has been developed with flexibility, scalability across sizes, and an expanded design space to meet the increased performance needs of intensified bioprocesses.

33. Risk Assessment For Carcinogenic Substances In The Lab 11/20/2023

    Learn how to apply the STOP hierarchy of protective measures to carcinogens and easily document the four key steps of risk assessment.

34. The Closed Processing Advantage: Optimizing Biopharma Facilities 11/16/2023

    Explore the evolving landscape of biopharma facility design and operations, including key market trends, closed processing benefits, and industry efforts to harmonize guidance and best practices.

35. Accelerate Development And De-Risk Gene Therapy Manufacturing 10/20/2023

    Join viral vector process and analytical development experts as they showcase strategies for developing robust processes and analytics for efficient and de-risked manufacturing.

36. Accelerated Monoclonal Antibody Development 9/26/2023

    Hear from some of the experts who were instrumental in developing the Accelerated mAb development program and work with biotech companies on a daily basis to accelerate their production timelines.

37. From Myth To Mastery: Unveiling The Secrets Of Virus Bank Manufacturing 9/12/2023

    It is crucial to start off your product development right. Here, you will learn how to best approach virus bank production. Review best practices, how to overcome common obstacles, and more.

38. Kick It Off Right: A Successful Cell Bank Manufacture 9/12/2023

    Learn about best practices for cell bank manufacturing, how to get the most out of your cell bank, the future of closed processing in line with Annex 1, and more.

39. Industry-Leading Lentiviral Titers Through Optimized Production Technology 8/28/2023

    See how VirusExpress' technology was optimized to provide industry-leading lentiviral titer and a streamlined approach to accelerate development timelines and de-risk manufacturing.

40. Characterizing AAV Encapsidated Nucleic Acid Sequences Using NGS 8/11/2023

    Here, we discuss the characterization of several representative AAV molecules using next-generation sequencing (NGS), including the sequencing process, bioinformatic analysis, and representative results.